| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: Results from the US societal and payer perspectives
|
Sussman, Matthew
|
|
2018
|
38 |
10 |
p. 1644-1657
|
article
|
| 2 |
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
|
Ashina, Messoud
|
|
2018
|
38 |
10 |
p. 1611-1621
|
article
|
| 3 |
Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab
|
Buse, Dawn C
|
|
2018
|
38 |
10 |
p. 1622-1631
|
article
|
| 4 |
Migraine with brainstem aura: Why not a cortical origin?
|
Demarquay, Geneviève
|
|
2018
|
38 |
10 |
p. 1687-1695
|
article
|
| 5 |
Peripheral vagal nerve stimulation modulates the nociceptive withdrawal reflex in healthy subjects: A randomized, cross-over, sham-controlled study
|
De Icco, Roberto
|
|
2018
|
38 |
10 |
p. 1658-1664
|
article
|
| 6 |
Reply to the letter by Min et al.
|
Kristoffersen, Espen Saxhaug
|
|
2018
|
38 |
10 |
p. 1701-1702
|
article
|
| 7 |
Serial testing of the ICHD-3 beta diagnostic criteria for probable reversible cerebral vasoconstriction syndrome: A prospective validation study
|
Lee, Mi Ji
|
|
2018
|
38 |
10 |
p. 1665-1671
|
article
|
| 8 |
Six-month clinical course and factors associated with non-improvement in migraine and non-migraine headaches
|
Aguila, Maria-Eliza R
|
|
2018
|
38 |
10 |
p. 1672-1686
|
article
|
| 9 |
Tolosa-Hunt Syndrome: Appraising the ICHD-3 beta diagnostic criteria
|
Mullen, Evan
|
|
2018
|
38 |
10 |
p. 1696-1700
|
article
|
| 10 |
Treatment of acute migraine by a partial rebreathing device: A randomized controlled pilot study
|
Fuglsang, Cecilia H
|
|
2018
|
38 |
10 |
p. 1632-1643
|
article
|
Journal description